Showing 721-730 of 9757 results for "".
Advocating for the Specialty and Patient Safety
https://practicaldermatology.com/topics/practice-management/advocating-for-the-specialty-and-patient-safety/18702/George J. Hruza, MD, Past President of the American Society for Dermatologic Surgery (ASDS), sat down with DermTube Journal Club Host Nancy J. Samolitis, MD to discuss the importance of getting involved with organizations like the ASDS and the American Academy of Dermatology Association to advocateGalderma, Allergan Rosacea News, Dupilumab Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-allergan-rosacea-news-dupilumab-data/18591/Galderma Laboratories launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33. The FDA has accepted Allergan's New Drug Application (NDA) filing for oxymetazoline cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema assoAnonymous Reviews on Google+ and How They Impact Your Dermatology Practice
https://practicaldermatology.com/topics/practice-management/anonymous-reviews-on-google-and-how-they-impact-your-dermatology-practice/18827/Online reviews are a fact of modern medical practice. Many physicians fret over negative reviews, but what about positive reviews? Learn how reviews influence your search rankings, how patients assess reviews, and how you can create a Google+ page that allows for anonymous reviews of your practice.Off-label Uses for Biologics
https://practicaldermatology.com/topics/psoriasis/off-label-uses-for-biologics/18964/Derm Insider Bonus Content: Host Neal Bhatia speaks with guests Alice Gottlieb, MD, Harold Farber, MD, and James Ulery, MD about various potential off-label uses for current and investigational systemic psoriasis therapies.Neotensil®: A Novel, Noninvasive Solution That Reduces the Appearance of Under-Eye Bags
https://practicaldermatology.com/topics/practice-management/neotensil-a-novel-noninvasive-solution-that-reduces-the-appearance-of-under-eye-bags/19058/Neotensil is the only noninvasive solution clinically proven to reduce the appearance of under-eye bags within an hour, with benefits that last up to 16 hours. Doris Day, MD, discusses the benefits of Neotensil, as well as patient selection, staff training and how to incorporate this unique and effeINTEGUMENT-OLE and What’s Next for Pediatric AD
https://practicaldermatology.com/series/skin-minute/integument-ole-study/56899/Pediatric dermatologist Larry Eichenfield, MD, talks about the INTEGUMENT-OLE study data and the impact of the roflumilast cream 0.05% (Zoryve) on the treatment of mild-to-moderate atopic dermatitis in children aged 2 to 5 years.Journal Club: S. Aureus-Driven AD Exacerbation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, EDrs. Rosen and Bhatia Highlight Latest Drugs at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/drs-rosen-and-bhatia-highlight-latest-drugs-at-maui-derm/32914/The current landscape of therapeutics for dermatologic conditions is dramatic, with new groundbreaking drugs continuously becoming available.Pediatric, Acne, and AD Sessions: Dr. Eichenfield
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/pediatric-acne-and-ad-sessions-dr-eichenfield/32684/Lawrence Eichenfield, MD, discusses his presentations from Maui Derm 2025, which included "Pediatric Dermatology 2025," "Update 2025: Acne and Rosacea," and "Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2025." Highlights include the importance of recognizing severe and rapidChronic Hand Eczema Treatment Landscape
https://practicaldermatology.com/series/c-suite-chats/chronic-hand-eczema-treatment-landscape/29126/Jacob Thyssen, MD, PhD, Chief Scientific Officer at Leo Pharma, talks about the incidence of chronic hand eczema and the advantage that delgocitinib provides compared to other treatment options.